NCT04612062View on ClinicalTrials.gov

A First-in-Human Study of CEE321 in Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 27, 2020

Primary Completion Date

May 16, 2021

Study Completion Date

May 16, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

CEE321

CEE321 administered to all subjects

Trial Locations (3)

21225

Novartis Investigative Site, Baltimore

91206

Novartis Investigative Site, Glendale

192-0071

Novartis Investigative Site, Hachiōji

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY